Summit shares drop after US FDA declines to approve lung cancer drug
Summit Therapeutics shares fell 20% premarket after the FDA declined to approve its lung cancer drug ivonescimab, citing insufficient overall survival benefits in a late-stage study. The drug was sought for advanced NSCLC patients with EGFR mutations. Analysts note the decision sets a regulatory precedent for similar drugs. Summit's shares were at $11.33 premarket.
How this was made

The 30-second read
Why it matters
The denial triggers a sharp price drop and may affect valuation of peer companies developing PD‑1/VEGF dual‑target therapies.
Market read
Regulatory outcome is a primary catalyst for Summit Therapeutics and could ripple through the oncology biotech sector.
What to watch
Summit's pipeline includes other indications and the recent acquisition from Akeso may provide longer‑term value.
Background
Summit Therapeutics sought FDA approval for ivonescimab in combination with chemotherapy for advanced non‑squamous NSCLC with EGFR mutations. The FDA cited lack of statistical significance in overall survival.
Ticker impact
Summit Therapeutics shares fell nearly 20% in pre‑market trading after the FDA declined to approve its lung‑cancer drug ivonescimab.
likely continued pressure as the market prices in the regulatory setback
Regulatory denial is a material catalyst for biotech stocks; the share price already dropped 19.9% pre‑market.
Market effects
Other lung‑cancer drug developers may see heightened scrutiny and valuation pressure.
US biotech sector likely faces short‑term weakness.
Moderate, as similar candidates abroad could be re‑evaluated.
Counterpoint
If ivonescimab shows promise in first‑line trials later this year, the stock could rebound on future upside.
Key entities
- companySummit Therapeutics
US‑listed biotech developing ivonescimab.
- regulatorFDA
U.S. Food and Drug Administration that declined the approval.




